Search

Relacatib

Terevalefim

Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).

XC221

XC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.

Dazostinag

Dazostinag is under investigation in clinical trial NCT04420884 (A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

G305

G305 is a [recombinant NY-ESO-1 protein] plus glucopyranosyl lipid A (GLA) in a stable emulsion (SE). G305 is an active component of CMB305 along with [LV305].[L47346]

Stannsoporfin

Stannsoporfin is a competitive heme oxygenase (HO) inhibitor being developed by InfaCare, a subsidiary of WellSpring Pharmaceuticals, for the prevention of hyperbilirubinemia in infants at risk of developing

CG7870

CG7870 is an oncolytic virus therapy for prostate cancer. … It is a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.

Palivizumab

Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). … Synagis is a composite of human (95%) and murine (5%) antibody sequences.

POT-4

POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD).

AZX-100